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Background: The effects of chronic treatment with tricyclic antidepressant (desipramine, DMI) on the hippocampal
transcriptome in mice displaying high and low swim stress-induced analgesia (HA and LA lines) were studied. These
mice displayed different depression-like behavioral responses to DMI: stress-sensitive HA animals responded to DMI,
while LA animals did not.
Results: To investigate the effects of DMI treatment on gene expression profiling, whole-genome Illumina Expres-
sion BeadChip arrays and qPCR were used. Total RNA isolated from hippocampi was used. Expression profiling was
then performed and data were analyzed bioinformatically to assess the influence of stress susceptibility-specific phe-
notypes on hippocampal transcriptomic responses to chronic DMI. DMI treatment affected the expression of 71
genes in HA mice and 41 genes in LA mice. We observed the upregulation of Igf2 and the genes involved in neuro-
genesis (HA: Sema3f, Ntng1, Gbx2, Efna5, and Rora; LA: Otx2, Rarb, and Drd1a) in both mouse lines. In HA mice, we
observed the upregulation of genes involved in neurotransmitter transport, the termination of GABA and glycine ac-
tivity (Slc6a11, Slc6a9), glutamate uptake (Slc17a6), and the downregulation of neuropeptide Y (Npy) and cortico-
tropin releasing hormone-binding protein (Crhbp). In LA mice, we also observed the upregulation of other genes
involved in neuroprotection (Ttr, Igfbp2, Prlr) and the downregulation of genes involved in calcium signaling and
ion binding (Adcy1, Cckbr, Myl4, Slu7, Scrp1, Zfp330).
Conclusions: Several antidepressant treatment responses are similar in individuals with different sensitivities to
stress, including the upregulation of Igf2 and the genes involved in neurogenesis. However, the findings also reveal
that many responses to antidepressant treatments, involving the action of individual genes engaged in
neurogenesis, neurotransmitter transport and neuroprotection, depend on constitutive hippocampal transcriptomic
profiles and might be genotype dependent. The results suggest that, when and if this becomes feasible,
antidepressant treatment should take into consideration individual sensitivity to stress.* Correspondence: p.lisowski@ighz.pl
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The hippocampus is an integral component of the limbic
system and mechanisms that control mood [1,2]. The
hippocampus also plays an important role in stress, pain
and nociceptive responses and might mediate depressive
behaviors [3]. Because the propensity to develop depres-
sion and the responses to antidepressant treatments
might depend on the susceptibility of an individual to
stress, we studied mice selected for high (HA line) or
low (LA line) stress reactivity, as measured by the mag-
nitude of swim stress-induced analgesia (SIA) [4]. There
were differences among the mice in terms of responses
to a variety of antidepressants (desipramine, venlafaxine,
and aminosenktide) and profound differences in tail sus-
pension and forced swim tests, reflecting depression-like
behaviors [5-7]. Under control conditions, clear differ-
ences in the constitutive, hippocampal transcriptomic
profiles related to the upregulation of genes involved in
calcium signaling in LA mice and the robust upregula-
tion of genes encoding receptors for neurotensin (Ntsr2)
and GABA (Gabard) in HA mice were observed [8].
These findings suggested that the selective breeding for
swim SIA affected many aspects of hippocampal neuron
physiology, including metabolism, structural changes and
cellular signaling. Furthermore, unpredictable chronic
mild stress (CMS), used to trigger desipramine-reversible
depressive-like behavior [9], produced mouse line-specific
responses in hippocampal gene expression [10]. The re-
sults suggest that hippocampal responses to stress depend
on genotype, and the potential drug targets against the
detrimental effects of stress might include glutamate
transport, neurogenesis, axonogenesis, neurite develop-
ment, or chromatin modifications, to name a few.
The present study was conducted to identify transcrip-
tomic response involved in the action of the tricyclic
antidepressant, desipramine, in the hippocampus. We used
expression microarray analyses to characterize changes in
the transcription profiles and identify genes that are af-
fected after chronic treatment with DMI in the hippocam-
pus of the two distinct mouse lines selected for stress
reactivity. The results provide insight into the genetic back-
ground that might modulate the molecular response to an-
tidepressants and mediate resistance to antidepressants.
Methods
Animals
Swiss-Webster male mice (weighing 25–30 g, 12 weeks
old) exhibiting high (HA) and low (LA) swim stress-
induced analgesia (SIA) were used [4]. Briefly, the outbred
male and female mice were scored for the latency of the
hind paw nociceptive reflex on a 56°C hot plate at 2 min
after the completion of a 3-min swimming test in 20°C
water. The animals displaying the longest (50 – 60 s) and
the shortest (<10 s) post-swim latencies of the nociceptiveresponse were selected as progenitors of the HA and LA
lines. A similar procedure was repeated in subsequent off-
spring, and the animals displaying the longest and the
shortest post-swim hot plate latencies were mated to
maintain the lines or selected for use in subsequent exper-
iments. The HA and LA male mice used in the present
experiment belonged to the 68th generation of albino
Swiss–Webster mice that have been selectively bred in
our laboratory for high (HA line) and low (LA line)
magnitudes of swim-stress induced analgesia (SSIA) as de-
scribed earlier [4].
Animals were males, 5 months old and weighed 41.5 ±
0.8 g and 39.5 ± 0.5 g (HA and LA lines, respectively).
Mice from each line and treatment group were housed
four to six per cage on a 12-h/12-h light dark cycle with
unlimited access to standard murine chow food and water.
All procedures were carried out between 9 am and 4 pm.
Mice from HA and LA lines were injected and decapitated
in a pseudorandom order.
Treatment
HA and LA animals were injected intraperitoneally with
desipramine (DMI, 7.5 mg/kg/day, Sigma-Aldrich, USA)
or saline once a day for 21 consecutive days. of the ex-
periment. Each experimental group contained 12 mice.
DMI was selected based on the results obtained from
our previous studies [5,6]. These studies revealed that
DMI shortened the immobility period of HA mice in the
forced swim and tail suspension tests but was ineffective
in LA animals. All procedures involving animals were
performed in accordance with the Guiding Principles for
the Care and Use of Research Animals, and were approved
by the the Institutional Ethics Committee of the Institute
of Genetics and Animal Breeding and then by the National
Third Local Ethics Commission (permission No. 3/2005).
Permission had been issued in accordance with the guide-
lines of the pertinent Polish Parliamentary Bill. All obser-
vations were performed by a trained observer who was
blinded to the treatment conditions and was not informed
of the treatment conditions in advance.
Samples preparation
Two days after the injections, the animals were sacrificed
through decapitation (HA DMI, n = 12; HA saline, n = 12;
LA DMI, n = 12; LA saline, n = 12), and the brains were
rapidly removed. The hippocampi were quickly dissected
on ice-cold glass, inserted into freezing vials, frozen in li-
quid nitrogen and stored at −80°C until further analysis.
Total RNA was isolated separately from each individual
hippocampus using the NucleoSpin RNA II kit (Macherey-
Nagel, Germany). A Nanodrop (Nanodrop, USA) and Bioa-
nalyzer (Agilent, USA) were used to estimate the quantity
and quality of each RNA sample, and the RIN (RNA Integ-
rity Number) values ranged from 9.2 to 9.8 for all samples.
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between the animals and the variation introduced through
dissection and tissue preparation, the individual RNA
samples from three mice were pooled. The quantity and
quality of the RNA in the pools were estimated using a
Nanodrop and Bioanalyzer. Each pool was subsequently
converted to biotinylated cRNA using the Illumina RNA
Amplification Kit (Ambion Inc., USA) and 100 ng of total
RNA, purified using the RNeasy kit (Qiagen, Germany)
and hybridized to a single microarray. Four independent
biological replicates of the microarray analysis were pre-
pared for each group of mice.
Microarray, hybridization and fluorescent detection
The gene expression profiling was performed using
MouseRef-8_V2 Expression BeadChip microarrays (Illumina,
USA) according to MIAME guidelines [11]. Each array
contains >22,000 well-annotated RefSeq 50-mer oligo-
nucleotide probes selected from the NCBI database
(Release 16). The cRNA samples were applied to the ar-
rays and assembled onto hybridization cartridges. Over-
all, 16 hybridizations (4 for each experimental group)
were performed. The hybridization and washing of the
arrays was performed according to the manufacturer’s
hybridization protocol. The microarrays were scanned
on a BeadArray Reader (Illumina, USA).
Data normalization, selection of the most differently
expressed genes and hierarchical clustering
Raw microarray data were processed using the BeadArray
and LIMMA package of the R statistical language (Biocon-
ductor project; [12]). The data preprocessing involved the
normalization of the expression levels using a quantile
method preceded by log2 transformation. Linear model
fitting was performed for the pre-processed dataset. The
coefficients of the obtained fitted models described the
differences between the RNA sources hybridized to the
arrays. The empirical Bayesian analysis was performed to
determine whether the contrast coefficients from the
linear models were equal zero and identify differentially
expressed genes. The genes showing log fold-changes
greater than 0.5 (logFC > 0.5) and p < 0.05 were considered
significantly differentially expressed. The Benjamini and
Hochberg method [13], to control the false discovery rate
(FDR), was used to correct the p values.
Gene lists enrichment analysis
The gene lists (GenBank accession numbers) generated
from the microarray results were submitted to the
Database for Annotation, Visualization and Integrated
Discovery (DAVID) v6.7. [14]. The genes were classified
into functional categories using biological process (BP),
cellular components (CC), and molecular function (MF)
ontologies. Analysis of the association of the genes withphysiological or biochemical pathways was performed
using the Kyoto Encyclopedia of Genes and Genomes
database (KEGG; [15]). To identify significantly overrepre-
sented biological categories and KEGG pathways within
the lists of differentially expressed genes, the threshold for
the enrichment analysis was set at p ≤ 0.05. For details see
Lisowski et al., 2011 [10,16].
Quantitative real-time PCR (qPCR) for microarray
validation
To validate the results of the microarrays, quantitative real-
time PCR (qPCR) with SYBR Green was performed as pre-
viously described [10], according to MIQE guidelines [17].
Eight genes, belonging to different functional categories
and significantly differing in the expression between the sa-
line and desipramine experimental groups, were selected in
each line. The qPCR assays were performed in triplicate on
the same, non-pooled individual RNA samples, which were
used in the microarray experiment. All amplified PCR frag-
ments were sequenced to verify the resulting PCR product.
For reference, using a previously described methodology
[18,19], 10 common reference genes belonging to different
functional classes (Gapdh, Tbp, Hprt1, Actb, B2m, Rpl13a,
Hsp90ab1, Gusb, Tfrc, and Ppia) were assessed using qPCR,
and two housekeeping genes stably expressed in hippo-
campi of DMI-treated mice were used: TATA box binding
protein (Tbp) and hypoxanthine guanine phosphoribosyl
transferase 1 (Hprt1). The normalization factor (NF) was
obtained from the geometric mean of the raw expression
data of Tbp and Hprt1.
The primers were designed using ExonPrimer software
(Institute of Human Genetics, TUM/Helmholtz Center
Munich, Germany; [20]) and Mus musculus GenBank se-
quences. All primers produced amplicons spanning two
exons in highly conserved coding regions and included
all known alternatively spliced mRNA variants. Additional
file 1 summarizes the primer information, including gene
names, primer sequences, amplicon lengths, annealing
temperatures, and GenBank accession numbers.
The data from the triplicate qPCR reactions were nor-
malized using the average cycle threshold (Ct) value and
a mathematical model for the relative quantification of
the real-time RT-PCR results [21]. The qPCR data ob-
tained from the saline and DMI-treated groups were an-
alyzed using t-tests. The differences between the groups
were considered significant at p < 0.05. The degree and
significance of the correlation between fold-changes, as
determined in the microarray and qPCR analyses, were
evaluated using the Pearson moment correlation.
Results
Genome-wide gene expression
Comparisons of the hippocampal transcriptomic profiles
of the control and desipramine-treated animals revealed
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41 genes in LA mice, meeting the criteria of log fold-
changes greater than 0.5 and adjusted p values <0.05.
DMI treatment in HA mice, compared with saline injec-
tions, resulted in the upregulation of 57 transcripts and
the downregulation of 14 transcripts. DMI treatment in
LA animals resulted in upregulation of 28 transcripts
and downregulation of 13 transcripts. The entire set of
probes, with the corresponding gene names and the FC
and p values that differed between the saline- and DMI-
treated animals are presented in Additional files 2 and 3.
All genes annotated to these probe sets were expressed
in mouse hippocampus according to the Novartis Gene
Expression Atlas [22]. The cell-type classification analysis
of differentially expressed genes, according to Cahoy [23],
the GeneCards® database [24] screening and Ingenuity
Pathway Analysis® [25] of the major canonical pathways,
revealed that most of these genes are characteristic of neu-
rons and oligodendrocytes.
Effect of desipramine on hippocampal transcriptome in
HA line
DMI treatment in HA mice resulted in the upregulation of
transcripts involved in 12 significant (p < 0.05) biological
processes, 5 cellular components, 7 molecular function
terms and 2 biochemical pathways. The biological process
terms included neurotransmitter transport (p = 0.001)
(Slc6a9, Slc17a6, Slc6a11, Rims3), cell motion (p = 0.002)
(Vav3, Sema3f, Gbx2, Efna5, Elmo1), cell projection
organization (p = 0.003) (Vav3, Ntng1, Gbx2, Efna5), angio-
genesis (p = 0.005) (Gbx2, Arhgap24, Anxa2) axonogen-
esis/neuron differentiation/neuron projection (p = 0.004)
(Ntng1, Gbx2, Efna5, Rora), behavior (p = 0.039) (Ptgds,
Sema3f, Chrna4, Zic1) and neurogenesis (p = 0.048)
(Sema3f, Ntng1, Gbx2, Efna5, Rora). The cellular compo-
nent terms included elements of the cell junction (p =
0.0002) (Cbln1, Slc17a6, Syt9, Chrna4, Arhgap24, Calb2,
Anxa2, Rims3), plasma membrane (p = 0.001) (Slc6a11,
Ntng1, Syt9, Arhgap24, Calb2, Rims3, Anxa2, Ly6a, Gng8,
Slc6a9, Cbln1, Slc17a6, Chrna4), and the synapse (p =
0.011) (Cbln1, Slc17a6, Syt9, Chrna4, Rims3). The molecu-
lar function terms included amino acid transmembrane
transport (p = 0.007) (Slc6a9, Slc17a6, Slc6a11) and che-
morepellent activity (p = 0.01) (Sema3f, Efna5). To identify
significantly over-represented pathways in the list of DMI-
upregulated genes, we searched the KEGG database. In the
hippocampus of HA mice, the significantly overrepresented
pathways included chemokine signaling (p = 0.003) (Gng8,
Vav3, Prkcd, Elmo1) and axon guidance pathways (p =
0.021) (Sema3f, Ntng1, Efna5).
The downregulated transcripts were involved in 6 signifi-
cant (p < 0.05) biological processes and 1 cellular compo-
nent term, including mast cell (p = 0.009) and myeloid
leukocyte activation (p = 0,02), the regulation of responseto external stimulus (p = 0.023) and vesicle-mediated trans-
port (p = 0.029) (Cplx2, Fcer1g, Npy, Arc) and coding ele-
ments of synapses (p = 0.026) (Phactr1, Arc, Cplx2).
Moreover, as shown in Additional file 1: Table S1,
DMI treatment resulted in the upregulation of neurona-
tin (Nnat), a factor involved in the modulation of den-
dritic calcium levels during homeostatic plasticity, and
the downregulation of neuropeptide Y (Npy), which is im-
plicated in a diverse range of biological actions, including
anxiolysis and the control of gonadotrophin-releasing hor-
mone or pituitary hormone secretion. DMI also caused
the downregulation of corticotropin-releasing hormone-
binding protein (Crhbp), which inactivates CRH. For the
list of GO functional category classifications of up- and
down-regulated genes affected after DMI treatment in the
HA line see Additional file 4.
Effect of desipramine on hippocampal transcriptome in
the LA line
The genes upregulated in LA mice after DMI treatment
are involved in 13 significant (p < 0.05) biological processes
and 2 cellular component terms. The biological process
terms included behavior (p = 0.021), including behavioral
interactions (p = 0.045), mating (p = 0.016), reproduction
(p = 0.028) and locomotory behavior (p = 0.048) (Pde1b,
Ppp1r1b, Enpp2, Drd1a), brain structure development,
including striatum (p = 0.015), subpallium (0.019), eye
(p = 0.022) and forebrain (p = 0.025), and neurogenesis
(p = 0.03) (Otx2, Rarb, Drd1a). The cellular component
terms included elements of the extracellular space (p =
0.006) and extracellular region (p = 0.035) (Ttr, Kl, Enpp2,
Sostdc1, 1500015o10rik, Tac1, Igf2, Igfbp2). The molecular
function terms and biochemical pathways were not in-
cluded in the list of upregulated genes in LA mice and
were not statistically significant. The downregulated
genes in the LA mice transcriptomes were not signifi-
cantly enriched.
Notably, the transcripts upregulated after DMI treat-
ment in LA mice include transthyretin (Ttr), the prolac-
tin receptor (Prlr), insulin-like growth factor 2 (Igf2),
and insulin-like growth factor binding protein 2 (Igfbp2),
which are important genes involved in neuroprotection.
For the list of GO functional category classifications of
up- and down-regulated genes affected after DMI treat-
ment in the LA line see Additional file 5.
Quantitative real-time PCR (qPCR) for microarray
validation
To validate the microarray results, 16 (8 from HA and 8
from LA) differentially expressed genes (DEGs) were se-
lected for quantification using qPCR. The DEGs were
selected from among the significant functional groups
associated with neurotransmitter transport, immunity, cell
differentiation, neurogenesis, axonogenesis, and calcium
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genes were selected for the HA line: Chrna4, Crhbp,
Gbx2, Igf2, Nnat, Npy, Slc6a11, and Slc17a6. The follow-
ing genes were selected for the LA line: Cckbr, Csrp1,
Drd1a, Igf2, Igfbp2, Otx2, Prlr, and Ttr. Differences in the
expression revealed using microarray analyses were con-
firmed. The expression levels are shown in Figure 1. The
DEGs identified through microarray tests were consistent
with the qPCR results (R = 0.94, p < 0.0001).
Discussion
Early comparisons of the constitutive gene expression
profiles between the HA and LA lines identified 205
transcripts with different levels of mRNA in the hippo-
campi of non-stressed animals [8]. The results suggest
that individual differences in depression-like behavioral
patterns may be associated with the characteristics of
the constitutive hippocampal transcriptome.Figure 1 Validation of expression of the selected genes by qPCR. Salin
LA mice vs. desipramine-treated LA mice (B). Results are presented as mea
error indicators show ± S.E.M. Values differ significantly at *p < 0.05, **p < 0.
the raw expression data of two reference genes: Gapdh and Hprt1. Abbrevi
LA, low analgesia mice; S.E.M., standard error of measurement or mean; Tbp
phosphoribosyltransferase 1.The present study indicates that two different basal hip-
pocampal transcriptomic profiles influenced the response
to DMI, although common changes induced through drug
treatments were also observed. The putative genes associ-
ated with the action of the ADs in the brain based on the
literature search indicated that chronic AD treatments in-
crease the levels of the cAMP response element-binding
protein (CREB) mRNA and its receptor trkB in the hippo-
campus [26-28]. Furthermore, other transcription factors,
such as Fos family members, are also increased in the brain
after the chronic administration of ADs [29,30]. Anti-
depressant drugs produce antidepressant effects in the pre-
frontal cortex and hippocampus [31]. Experiments have
demonstrated that antidepressants significantly affect the
cAMP cascade, and a homologous pathway exists for all
classes of antidepressants. However, other observations,
using different biochemical and molecular assays, suggest
limited changes. Thus, genes encoding cytochrome b [32],e-treated HA mice vs. desipramine-treated HA mice (A); saline-treated
ns of relative mRNA levels in 12 individuals per experimental group;
01 or ***p < 0.001; qPCR values were normalized to geometric mean of
ations: qPCR, quantitative real-time RT-PCR; HA, high analgesia mice;
, TATA box binding protein; Hprt1, hypoxanthine
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the RING-H2 finger motif gene [34], the cysteine string
protein [35], the tetraspan protein [36], the GRB2 homeo-
box protein and the ribosomal protein L35a [37], isoforms
of protein kinase C and cAMP-dependent protein kinase
[38], the Mss4 gene [39], VAMP2/synaptobrevin-2 [40], and
GAP-43 [41] are regulated through treatment with antide-
pressants in different parts of the rodent brain. Long-lasting
neuroadaptations likely include complex changes in the
gene expression in the limbic system of the brain. For ex-
ample, changes in the expression of Crhbp and Npy (down-
regulated in HA) after AD treatment have been reported
[42]. Evidence of the importance of ion transport in the rat
brain cortex has been shown in the context of antidepres-
sant treatment [43,44]. Specifically, changes in gene expres-
sion coding elements of calcium and sodium channels were
observed after 28 days of treatment with amitryptiline [45].
In the present study, downregulation of adenylate cyclase 1
(Adcy1) and the cholecystokinin B receptor (Cckbr) in-
volved in calcium signaling occurred in the LA line. In the
HA line, we observed the upregulation of neuronatin
(Nnat). A recent study showed that Nnat adjusts dendritic
calcium levels through the regulation of intracellular cal-
cium storage, thus neuronatin might impact synaptic plasti-
city through the modulation of dendritic calcium levels
during homeostatic plasticity, thereby potentially regu-
lating neuronal excitability, receptor trafficking, and cal-
cium dependent signaling in hippocampal neurons [46].
The results obtained in the present study, however, also
implicate a number of novel “AD genes”. Among these,
alterations in the expression of genes involved in neuro-
genesis (Sema3f, Ntng1, Gbx2, Efna5, Rora, Otx2, Rarb,
Drd1a) and neuroprotection (Ttr, Prl, Igf2) are of par-
ticular interest.
Effects of desipramine on genes related to neurogenesis
The chronic administration of antidepressants increases
the proliferation and survival of neural stem cells and new
neurons in the hippocampus [47-49]. Increased stem cell
proliferation is required for the behavioral effects of antide-
pressants, suggesting that this effect might underlie the
therapeutic action of antidepressant drugs on mood [50]. It
takes weeks for newborn neurons to differentiate and
mature into fully functional hippocampal granule neurons
[51], suggesting that the gradual maturation of newly born
dentate granule neurons might explain the delayed action
of antidepressant drugs [52]. Specific gene expression pro-
files of neurogenesis in AD treatment have not been clearly
identified, although according to Gene Ontology [53] clas-
sification, the upregulation of five genes in the HA line
(Sema3F, Ntng1, Gbx2, Efna5, Rora) and three genes in the
LA line (Otx2, Rarb, Drd1a) involved in neurogenesis,
neurite outgrowth, and the proliferation and differentiation
of neuronal progenitor cells were detected. Igf2 should beadded to the group of genes related to neurogenesis, as this
gene was upregulated in both lines after DMI treatment.
Effects of desipramine on genes related to the chronic
stress response
The analyses performed in the present work indicated a ro-
bust upregulation of Ttr gene-coding transthyretin (TTR)
and the Prlr gene-coding prolactin receptor in the LA line,
and in both lines, we observed the upregulation of the Igf2
gene encoding somatomedin. TTR is a carrier protein and
a major transporter of thyroid hormones and retinol in
plasma and cerebrospinal fluid [54]. The clinical features of
defects in TTR include seizures, stroke-like episodes,
dementia and psychomotor deterioration. However, the
antidepressant-like effect of the histone deacetylase inhibi-
tor sodium butyrate (SB) upregulates transthyretin (Ttr),
with simultaneous increases in histone H4 acetylation at
the promoter of the Ttr gene [55]. Moreover, the genes, in-
cluding Ttr, Prl and Igf2, whose hippocampal expression
patterns were downregulated in four rat models of en-
dogenous depression and chronic stress, represent a gener-
alized molecular response to chronic stress [56]. In
addition, stress has previously been shown to increase the
expression of neuropeptide Y [57-59], which in the present
study was downregulated in the HA line after DMI treat-
ment. Prolactin is a neuromodulator of behavioral and
neuroendocrine stress in the rat [60,61]. The downregula-
tion of brain prolactin receptors increased anxiety-related
behavior, demonstrating an anxiolytic effect of PRL in the
brain [61]. Furthermore the stress-induced increase of
corticotropin secretion was reduced after the chronic intra-
cerebroventricular infusion of PRL [61]. Fujikawa [62]
showed that PRL levels increase in response to stress acting
on the central nervous system to protect against acute
stress-induced hypocalcemia. Moreover, a recent study on
gene expression profiling in neural stem cells (NSCs)
showed the upregulation of insulin-like growth factor 2
(Igf2) in the dentate gyrus (DG) compared with that in im-
mature neurons. IGF2 selectively controls the proliferation
of DG NSCs in vitro and in vivo through AKT-dependent
signaling. Thus, the gene expression profiling of NSCs and
progeny cells revealed that IGF2 is a novel regulator of
adult neurogenesis [63]. Altogether, these findings suggest
the possibility that the upregulation of transcripts for Ttr,
Prlr in HA line, and Igf2 in both lines might be involved in
AD actions.
Effects of desipramine on the genes involved in
neurotransmitter transport
Among the genes involved in neurotransmission, micro-
array analysis revealed the upregulation of Slc6a, Slc17a6,
Slc6a11 (also Glyt1, Vglut2 Gat3 respectively) and Rab3.
Glyt1 terminates the action of glycine through high affin-
ity sodium-dependent reuptake into presynaptic terminals
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NMDA receptor-mediated neurotransmission. Vglut2 me-
diates the uptake of glutamate into synaptic vesicles at
presynaptic nerve terminals of excitatory neural cells.
Gat3 terminates the action of GABA through high affinity
sodium-dependent reuptake into presynaptic terminals
and Rab3 regulates synaptic membrane exocytosis. Be-
cause antidepressants inhibit GABA uptake, the upregu-
lation of Gat3 is an important factor in AD therapy.
Tordera [64] showed that repeated treatment with flu-
oxetine, paroxetine or desipramine increased the abun-
dance of Vglut1 mRNA in the hippocampus, but did not
increase the expression of Vglut2 and Vglut3 mRNA.
The data obtained in the present study suggest that a
course of AD drug treatment also increases the expres-
sion of Vglut2, another gene involved in the regulation
of glutamate secretion, but only in vulnerable individ-
uals, such as the HA mouse line.
The impact of desipramine treatment on HA and LA
mouse lines
The objective of the present study was to characterize the
transcriptional response to chronic desipramine treatment
in the hippocampus of mouse lines displaying robust dif-
ferences in the behavioral responses to ADs. In a previous
study, we showed that desipramine, venlafaxine and ami-
nosenktide shortened the immobility period of HA mice
in the forced swim and tail suspension tests, but were in-
effective in the LA line [5-7]. Moreover, at the molecular
level, the lines were characterized by differences in the
basal transcriptomic profile in the hippocampus, which in-
dicates that selective breeding for swim SIA affected many
aspects of hippocampal neuron physiology, including me-
tabolism, structural changes, and cellular signaling [8].
The genes involved in calcium signaling pathways are up-
regulated in LA mice, while HA mice are characterized by
the robust upregulation of Klf5 and genes encoding recep-
tors for neurotensin and GABA [8]. Klf5 encodes the
KLF5 zinc finger protein, which act as transcription fac-
tors that bind to GC box promoter elements and activate
the transcription of these genes, depending on the DNA
methylation status in the promoter regions. In turn, we
observed that chronic mild stress (CMS) generated a self-
contained response within each mouse line [10]. In the
HA line, CMS affected several genes involved in chroma-
tin modifications, suggesting a role for the epigenetic
regulation of the stress response in the HA line. KLF5 is
primarily localized in the hippocampus, which is the prin-
cipal source of glutamatergic neurotransmission. These
findings suggest that KLF5 gene expression is involved in
glutamatergic neurotransmission [65]. Altogether, the pre-
vious and current results on the hippocampal transcrip-
tion patterns of the genes involved in calcium signaling,
GABA neurotransmission, ion transport, and glutamatetransporters suggest a functional endpoint for structurally
unrelated antidepressants and explain the differences ob-
served in the lines in response to antidepressants.
Conclusions
The gene expression patterns during ADs treatment could
be very complex. Nevertheless, our study revealed a num-
ber of novel potential targets for antidepressant therapy,
such as the Npy, Crhbp, Ttr, Igfbp2, Prlr, and genes in-
volved in neurogenesis that were not previously linked to
antidepressant action. Potential drug targets against the
detrimental effects of stress and depression include also
glutamate transporters, GABA neurotransmission, and
neuro- and axonogenesis, and suggest that pharmacother-
apy might be genotype dependent. Single nucleotide poly-
morphisms (SNPs), epigenetic statuses or epimutations in
the regulatory elements of the identified genes should be
considered in the pharmacogenomics of antidepressants.
Genome wide gene expression profiling using two lines of
mice bred for stress reactivity facilitates the elucidation of
broader mechanisms underlying antidepressants effects.
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